Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Bexxar

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The study aimed at identifying patient-specific dosimetric and nondosimetric factors predicting outcome of non-Hodgkin lymphoma… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2009
2009
IntroductionThe American Cancer Society estimated 66,120 new cases of non-Hodgkin lymphoma (NHL) in the USA in 2008… Expand
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Review
2007
Review
2007
  • T. Karagiannis
  • Hellenic journal of nuclear medicine
  • 2007
  • Corpus ID: 32391781
Currently, beta-emitting radionuclides are used almost exclusively in the clinic and in clinical radioimmunotherapy studies. The… Expand
  • table 1
  • figure 1
2005
2005
Advanced follicular lymphomas (FL) are incurable with conventional chemotherapy regimens. The Southwest Oncology Group… Expand
2004
2004
6520 Background: A phase II, open-label, multicenter study was conducted to determine the efficacy of Bexxar therapy following… Expand
2004
2004
6518 Background: The sequential combination of chemotherapy and radioimmunotherapy offers a novel strategy for the initial… Expand
2004
2004
6518 Background: The sequential combination of chemotherapy and radioimmunotherapy offers a novel strategy for the initial… Expand
2004
2004
6575 Introduction: The Bexxar therapeutic regimen can produce durable and complete responses in patients with relapsed/refractory… Expand
Review
2002
Review
2002
  • B. Cheson
  • Current opinion in investigational drugs
  • 2002
  • Corpus ID: 7664533
Bexxar (131I tositumomab) is a radiolabeled anti-CD20 monoclonal antibody for the treatment of relapsed and refractory follicular… Expand
2002
2002
Radioimmunotherapy (RIT) with Bexxar (tositumomab and iodine‐131 tositumomab; Coulter Pharmaceutical, South San Francisco, CA… Expand